THURSDAY, Sept. 12, 2024 -- For patients with resectable non-small-cell lung cancer (NSCLC), perioperative nivolumab is associated with event-free...
Vous n'êtes pas connecté
New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with resectable NSCLC who received adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery compared to those who received only neoadjuvant nivolumab plus chemotherapy. The data was reported at the International Association for the Study of Lung [...]
THURSDAY, Sept. 12, 2024 -- For patients with resectable non-small-cell lung cancer (NSCLC), perioperative nivolumab is associated with event-free...
Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete...
Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete...
Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete...
New data presented today reveals that the PanCan nodule management protocol demonstrates superior performance in triaging lung cancer screening...
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated...
In contrast to other commonly diagnosed cancers like colorectal and lung cancer, the 5-year survival rate after diagnosis for pancreatic cancer is...
WEDNESDAY, Sept. 18, 2024 -- Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b...
9 September 2024 -- Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival...
9 September 2024 -- Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival...